Aldesleukin

Related Multimedia

Click on an icon to view.

Clinical Effects of Aldesleukin

Aldesleukin has been studied in people with metastatic kidney cancer and those with metastatic skin cancer. In the studies involving kidney cancer, 7 percent of people given aldesleukin had no evidence of cancer after treatment and 8 percent had at least a partial response to treatment. The response lasted from 3 to over 131 months.

In the studies involving skin cancer, 6 percent of people given aldesleukin had no evidence of cancer after treatment and 10 percent had at least a partial response to treatment. The response to treatment lasted from 1 to over 122 months.

When and How to Receive This Medication

Some general considerations to keep in mind during treatment with aldesleukin include the following:

This medication is given as a slow injection into a vein (an intravenous, or IV, infusion), every eight hours for five days, followed by a nine-day break, and then an additional five days of treatment.

The injection is normally administered by a healthcare provider in a healthcare setting, such as a hospital.

It takes 15 minutes to complete each aldesleukin IV infusion.

Your healthcare provider may give you other medicines to help prevent or manage certain side effects.

Aldesleukin should be inspected before use, and should not be given if it contains particles or is discolored.

For the medication to work properly, it must be used as prescribed.

Dosing Information for Aldesleukin

The dose of aldesleukin your healthcare provider recommends will vary, depending on how well you tolerate the medication. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.

(Click Aldesleukin Dosage for more information.)

Aldesleukin Article Continues on Next Page >

<< Prev

Next >>